Logo
x

Search

Subscribe Now

Innovent Biologics

Innovent Biologics Collaborates with Roche to Develop IBI3009 for SCLC

Innovent Biologics Collaborates with Roche to Develop IBI3009 for SCLC

  • January 2, 2025
Innovent Biologics Reports the P-II Trial Data of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis

Innovent Biologics Reports the P-II Trial Data of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis

  • October 17, 2024
The NMPA Approves Innovent Biologics’ Dupert (Fulzerasib) to Treat NSCLC

The NMPA Approves Innovent Biologics’ Dupert (Fulzerasib) to Treat NSCLC

  • August 22, 2024
Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes

Innovent Biologics Reports the P-III Trial Results of Mazdutide for Treating Type 2 Diabetes

  • May 9, 2024
Innovent’s IBI343 a Monotherapy Receives the NMPA’s Breakthrough Therapy Designation for Advanced Gastric Cancer (GC)

Innovent’s IBI343 a Monotherapy Receives the NMPA’s Breakthrough Therapy Designation for Advanced Gastric Cancer (GC)

  • May 7, 2024
Innovent Reports Results from the P-III (RESTORE-1) Study of IBI311 for the Treatment of Thyroid Eye Disease

Innovent Reports Results from the P-III (RESTORE-1) Study of IBI311 for the Treatment of Thyroid Eye Disease

  • February 20, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.